Ordinary Index Rebalancing in the Solactive China Healthcare Disruption Index | February 2022

In the ordinary rebalance the following composition will be implemented effective open 01.03.2022:

3SBIO INC
AKESO INC
ALIBABA HEALTH INFORMATION TECHNOLOGY LTD
ALPHAMAB ONCOLOGY
ANGELALIGN TECHNOLOGY INC
BEIGENE LTD
BRII BIOSCIENCES LTD
CARSGEN THERAPEUTICS HOLDING
CHINA MEDICAL SYSTEM HOLDINGS LTD
GENSCRIPT BIOTECH CORP
GRAND PHARMACEUTICAL GROUP LTD
GUSHENGTANG HOLDINGS LTD
HANSOH PHARMACEUTICAL GROUP CO
INNOCARE PHARMA LTD
INNOVENT BIOLOGICS INC
JD HEALTH INTERNATIONAL INC
JOINN LABORATORIES CHINA C-H
KANGJI MEDICAL HOLDINGS LTD
LIFETECH SCIENTIFIC CORP
MICROPORT CARDIOFLOW MEDTECH
MICROPORT SCIENTIFIC CORP
NEW HORIZON HEALTH LTD
PEIJIA MEDICAL LTD
PING AN HEALTHCARE AND TECHNOL
REMEGEN CO LTD-H
SHANDONG WEIGAO GROUP MEDICAL POLYMER CO LTD
SHANGHAI JUNSHI BIOSCIENCES CO LTD
SHANGHAI MICROPORT MEDBOT GR
SIMCERE PHARMACEUTICAL GROUP
SINO BIOPHARMACEUTICAL LTD ORD
VENUS MEDTECH HANGZHOU INC
WUXI APPTEC CO LTD
WUXI BIOLOGICS CAYMAN INC
YIDU TECH INC
ZAI LAB LTD